Skip to content

Clinical observation of flumazenil after gynecological day surgery under remazolam general anesthesia

Clinical observation of flumazenil after gynecological day surgery under remazolam general anesthesia

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300074137
Enrollment
Unknown
Registered
2023-07-31
Start date
2023-08-01
Completion date
Unknown
Last updated
2023-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Self-funded

Interventions

Experimental group:flumazenil 0.2mg

Sponsors

Weifang People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 20 Years

Inclusion criteria

Inclusion criteria: 1. Gynecological patients who are scheduled to undergo hysteroscopy under total intravenous anesthesia; 2. ASA I-II grade; 3. BMI 18-30; 4. Aged 18-70years.

Exclusion criteria

Exclusion criteria: 1. Patients who are allergic to any ingredients such as benzodiazepine opioids propofol and micuramide; 2. Patients with schizophrenia and severe depression; 3. Acute upper respiratory tract infection; 4. Poorly controlled severe hypertension; 5. History of alcohol abuse and long-term use of sedative analgesics and history of allergies; 6. Markov airway classification grade IV, those who require awake tracheal intubation as determined by the investigator; 7. Breastfeeding period female; 8. Other circumstances determined by the researcher to be unsuitable for selection; 9. The operation time is more than 1 hour; 10. Patients who have been hospitalized for more than 24 hours; 11. Patients who have been dropped out after surgery.

Design outcomes

Primary

MeasureTime frame
Incidence of nausea and vomiting within 24 hours after surgery;

Secondary

MeasureTime frame
Time of patient awakening;The incidence of pain in patients within 24 hours after surgery;Adverse event rate;

Countries

China

Contacts

Public ContactJi Fanceng

Weifang People's Hospital

jifanceng@163.com+86 135 6369 8838

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026